Opinion
The advantages of using circular RNAs—including increased durability, enhanced protein expression and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.
Restructuring can invite lawsuits if companies aren’t careful. Following local, state and federal rules is critical, as is keeping the employee handbook current.
Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
Artificial intelligence is making it faster to get drug candidates to the clinic, but to gain a competitive advantage, companies must have a strong foundation of data.
It’s important to maintain anonymity when seeking your next executive role, as your departure could impact other employees and the organization.
Continuing investment in basic infectious disease research and pandemic preparedness infrastructure isn’t just about being ready for the next pandemic—it’s also a smart business move.
Shifts in the FDA’s approach present an unprecedented opportunity to solve problems with patient access and trial design.
Plus, what to do if your offer is paused and how to manage work anxiety.
Tempting as it may be to turn to full automation to meet burdensome requirements, the potential for hallucination and other issues means biopharma companies must proceed with caution.
With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for Guillain-Barre syndrome with its investigational antibody, ANX005. The candidate is also being trialed in Huntington disease and ALS.